Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial
By Anvee Bhutani
Palisade Bio shares rose Monday after the company said the Food and Drug Administration cleared its investigational new drug application for PALI-2108, allowing it to begin a Phase 2 trial in patients with ulcerative colitis.
Shares of the biopharmaceutical company were recently up about 12% at $2.12.
The company said it plans to begin enrolling patients in the global Phase 2 ASCENTRA-UC study in the second half of 2026, with primary results expected in the second half of 2027.
The trial is expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe. It will evaluate two dose levels of PALI-2108 against a placebo.
Palisade also said it expects to submit an investigational new drug application in the second half of 2026 for a Phase 2 study of PALI-2108 in Crohn's disease.
Write to Anvee Bhutani at anvee.bhutani@wsj.com.
(END) Dow Jones Newswires
June 29, 2026 10:43 ET (14:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
The 10 Best Dividend Stocks
United States